(3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-methoxymethoxymethylphenylamino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid | 805242-17-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-methoxymethoxymethylphenylamino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid
• 英文别名: (3R,5R)-7-[2-(4-fluorophenyl)-4-[[4-(methoxymethoxymethyl)phenyl]carbamoyl]-3-phenyl-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid
• CAS: 805242-17-5
• 化学式: C₃₆H₄₁FN₂O₇
• 分子量: 632.729
• InChiKey: YTIRSFQCXBCOMI-LOYHVIPDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  46
• 可旋转键数：
  16
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  130
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• Substituted pyrrole derivatives and their use as HMG-CO inhibitors
  申请人：Ranbaxy Laboratories Limited

  公开号：EP2319843A1

  公开（公告）日：2011-05-11

  The present invention relates to substituted pyrrole derivatives, which can be used as 2-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Compounds disclosed herein can function as cholesterol lowering agents and can be used for the treatment of cholesterol-related diseases and related symptoms. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and methods of treating cholesterol-related diseases and related symptoms.

  本发明涉及可用作 2-羟基-3-甲基戊二酰辅酶 A（HMG-CoA）还原酶抑制剂的取代吡咯衍生物。本文公开的化合物可作为降低胆固醇的药物，并可用于治疗胆固醇相关疾病及相关症状。本文提供了制备所公开化合物的工艺，以及含有所公开化合物的药物组合物和治疗胆固醇相关疾病及相关症状的方法。
• SUBSTITUTED PYRROLE DERIVATIVES AND THEIR USE AS HMG-CO INHIBITORS
  申请人：RANBAXY LABORATORIES, LTD.

  公开号：EP1658283A2

  公开（公告）日：2006-05-24
• PHARMACEUTICAL COMBINATION COMPRISING ATORVASTATIN DERIVATIVES
  申请人：Ranbaxy Laboratories Limited

  公开号：EP1948165A1

  公开（公告）日：2008-07-30
• Pharmaceutical Combination
  申请人：Sattigeri Jitendra A.

  公开号：US20080248035A1

  公开（公告）日：2008-10-09

  This invention relates to a combination product or medicament comprising at least one novel substituted pyrrole derivative and one or more dyslipidemic agents, antiobesity agents, antihyperglycaemic agents, anti-inflammatory agents or mixture thereof. Also provided herein are the pharmaceutical compositions comprising at least one novel substituted pyrrole derivative and one or more dyslipidemic agents, antiobesity agents, antihyperglycaemic agents, anti-inflammatory agents or mixture thereof and optionally together with at least one pharmaceutically acceptable carrier, and methods for the treatment or prophylaxis of cardiovascular diseases, Alzheimer's disease, obesity, diabetes or inflammatory diseases comprising administering to a mammal in need thereof therapeutically effective amounts of combination pharmaceutical composition comprising at least one novel substituted pyrrole derivative and one or more dyslipidemic agents, antiobesity agents, antihyperglycaemic agents, anti-inflammatory agents or mixtures thereof.
• Substituted Pyrrole Derivatives And Their Use As HMG-CO Inhibitors
  申请人：Salman Mohammad

  公开号：US20100056602A1

  公开（公告）日：2010-03-04

  The present invention relates to substituted pyrrole derivatives, which can be used as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Compounds disclosed herein can function as cholesterol lowering agents and can be used for the treatment of cholesterol-related diseases and related symptoms. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and methods of treating cholesterol-related diseases and related symptoms.